Status:
COMPLETED
Pharmacokinetic Study of Patients Who Undergo Cycloserine, a 2nd-line Antituberculosis Medicament
Lead Sponsor:
Taipei Medical University WanFang Hospital
Collaborating Sponsors:
Centers for Disease Control, Taiwan
Conditions:
Pulmonary Tuberculosis
Eligibility:
All Genders
Brief Summary
In all treatments of tuberculosis, the second-line drugs are usually less effective but have more drug toxicity than the first-line ones. For the multidrug-resistant tuberculosis (MDR-TB) patients, wh...
Detailed Description
In all treatments of tuberculosis, the second-line drugs are usually less effective but have more drug toxicity than the first-line ones. For the multidrug-resistant tuberculosis (MDR-TB) patients, wh...
Eligibility Criteria
Inclusion
- 5 days and more of Cycloserine taking
- Asians
Exclusion
- Cancer patients
- AIDS patients
- Combined AIDS-TB patients
- Pregnant subjects
- Anyone whose medical and medication records are unclear
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01002170
Start Date
May 1 2009
End Date
May 1 2010
Last Update
November 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Medical University-Wan Fang Hospital
Taipei, Taiwan, 116